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A B ST R AC T 
 
 
The gastrointestinal microbiome contains at least 100 trillion 
microorganisms (bacteria, viruses, fungi), whose distribution varies from the 
mouth to the rectum spatially and temporally throughout one's lifetime. The 
microbiome benefits from advancing research due to its major role in human 
health. Studies indicate that its functions are immunity, metabolic processes 
and mucosal barrier. The disturbances of these functions, dysbiosis, 
influence physiology, lead to diabetes, inflammatory bowel disease, obesity 
and colon tumorigenesis. The third most common form of cancer, colorectal 
cancer, is the result of many factors and genes, and although the link between 
dysbiosis and this type of cancer is poorly characterized, it has been shown 
that some bacterial species and their metabolites have a critical role in 
developing colorectal cancer. Also, gut microbiota plays a role in the 
inflammatory response and immune process perturbations during the 
progression of colorectal cancer. Some new technologies, such as 
metagenome sequencing, facilitated the progress by analyzing the metabolic 
and genetic profile of microbiota, revealing details about the bacterial 
composition, host interactions, and taxonomic alterations. This review 
summarizes the studies regarding the link between gut microbiota and 
colorectal cancer, targeting new therapeutic strategies.   
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Dysbiosis or the alteration of the gut microbiome's 
composition has recently been associated with various 
human diseases, including even cancer [1]. A possible 
mechanism through which the microbiota could influence 
carcinogenesis is the biosynthesis of chemical carcinogens 
such as N-nitroso compounds or acetaldehyde by microbes, 
associated with dysbiosis-related inflammation [2]. It was 
estimated that more than 70% of the human microbiome is 
located in the colon, so this part of the digestive tract is 
considered to be its most heavily colonized section [3]. It 
may be the reason why the colon is more prone to 
developing cancer, in contrast with the small intestine (the 
cancer incidence is 12-fold higher in the colon compared 
to the small intestine) [4]. It is important to know that the 
lifestyle and the dietary habits corroborated with other risk 
factors including advanced age, impaired glucose 
metabolism, pro-inflammatory states, previous therapies 
such as antibiotic therapy, chemotherapy, co-morbidities 
modulate the gut microbiota; that is maybe why the 
microenvironment created by the alterations of the typical 
resident colonic flora could be more favorable to tumor 
development at this level [5-8]. Many studies report 
specific alterations in the gut microbiome associated with 
colorectal cancer; that is why it was taken into 
consideration as a screening method, being very important 
in the early diagnosis (early diagnosed patients with 
colorectal cancer (stages 0, I or II), have 80% survival rates 
over five years in contrast with the ones diagnosed in stage 
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IV that have only a 10% survival rate). Therefore, a 
promising strategy for the early diagnosis of colorectal 
cancer is the detection of specific microbiome alterations 
[9-13]. 
Discussions 
1. Human microbiota  
1.1 Microbial species 
The human body is colonized by a complex of the 
symbiotic, commensal and pathogenic microbial 
community. The human microbiome does not only include 
bacteria, but also fungi, protozoa and viruses [14,15]. A 
comprehensive group of living organisms considered a 
domain of life themselves are bacteria, many major 
bacterial phyla compose the human microbiota. Among 
them, the majority can be assigned to four types: 
Firmicutes, Bacteroidetes, Actinobacteria and 
Proteobacteria [16]. Firmicutes and Bacteroidetes 
represent more than 90% of the gut microbiome [17]. 
Firmicutes are composed mainly of Clostridia (Gram-
positive and anaerobic) and Bacilli (obligate or facultative 
aerobics) [18,19]. Actinobacteria (for example, 
Bifidobacterium) are multiple branching rods, Gram-
positive, non-spore-forming, non-motile and anaerobic 
bacteria. The phylum Bacteroidetes is composed of non-
spore, Gram-negative bacteria. Proteobacteria (for 
instance, Escherichia, Klebsiella, Enterobacter) are aerobic 
or facultative anaerobic, non-spore-forming rod, Gram-
negative bacteria [20]. 
There is a concept called “enterotype clusters”, through 
which the microbiota structure and different microbial 
colonization are better defined in various cohorts. It also 
allows the classification of each person by the relative 
abundance of specific bacterial in the fecal samples. The 
results of the studies performed on Japanese, American and 
European subjects confirm three clusters dominated by 
Bacteroides (enterotype 1), Prevotella (enterotype 2) and 
Ruminococcus (enterotype 3); each one of these three types 
is characterized by the relative abundance of metabolic 
pathways and by specific taxonomic composition [21]. 
1.2   Inflammatory and immune responses 
The microbiota composition varies according to the 
various locations along the gastrointestinal tract. Microbial 
dysbiosis can be the result of the dysregulation of the 
intestinal immune system. 
There is a delicate balance between the immune system 
and immune-regulatory functions, because the loss of a 
specific species can suppress the innate immune system or 
an overreaction. There is an immunological and physical 
barrier in the intestinal mucosa, between the luminal 
bacteria and the underlying immune cells, called intestinal 
epithelial cells; hematopoietic cells and intestinal epithelial 
cells generate various receptors named pattern recognition 
receptors; these mediate the interactions between the 
commensal microbiota and the immune system [22]. Toll-
like receptors and nuclear oligomerization domain-like 
represent some pattern recognition receptors; these 
recognize microbial molecules (microbe-associated 
molecular patterns - lipid A, lipopolysaccharides, flagella, 
peptidoglycans and microbial RNA/DNA) and activate 
inflammasomes such as TNF alpha, cytokines and IL-1 
beta [23]. 
It is essential to understand how and when dysbiosis 
and the genetic defects in the mucosa-intestinal epithelial 
cells and innate regulatory mechanisms can lead to the 
development of inflammatory or infectious diseases [24]. 
1.3 The metabolic role 
Recent studies have revealed that the gut microbiota 
can generate genotoxic or metabolite stress in the intestinal 
environment and thus, genetic and epigenetic changes are 
facilitated and lead to cancer. As to provide the repair of 
DNA damage and energy for multidrug resistance efflux 
pumps, glycolysis will generate adenosine triphosphate 
and nicotinamide adenine dinucleotide for the polymerase. 
That is why enhanced glycolysis can have an impact on 
drug resistance. Glucose metabolism can be improved by 
dietary fiber that increases the abundance of Prevotella. An 
increased amount of Prevotella in the gut microbiota 
protects against Bacteroides induced glucose intolerance. 
The last one may facilitate drug resistance and also could 
affect the tumor growth. Increased glycolysis enables the 
diversion of glycolytic metabolites into other important 
biosynthetic pathways that play an essential role in cell 
proliferation. That is why the control of gut microbiota and 
their metabolites can be a useful strategy in reducing drug 
resistance [25,26]. 
It has been shown that chronic low-grade inflammation, 
promoted by lipopolysaccharides, is linked to the 
occurrence of insulin resistance and obesity. These 
endotoxins may cross the gut mucosa by infiltrating 
chylomicrons or weak intestinal junctions, stimulating the 
absorption of cholesterol and dietary triglycerides from the 
gut to the plasma, producing a natural immune response. 
Compared to healthy individuals, the level of circulating 
endotoxins was 20% higher in people with glucose 
intolerance or obesity, and 125% higher in type 2 diabetes 
individuals. These elevated levels were also correlated with 
high concentrations of TNF- α and IL-6 in adipocytes. 
Also, a diet poor in fruit and fiber, but rich in high-
carbohydrates or high-fat, triggers the systemic secretion 
of lipopolysaccharides, the expression of Toll-like receptor 
4, nuclear factor κB and the suppression of cytokines. 
These factors regulate the pathways involved in insulin 
secretion [27-30]. 
The microbiota plays an important role in many aspects 
of the metabolism and brain functions. Several studies 
reveal the importance of microbiota and micronutrients in 
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attention deficit hyperactivity disorder in children. 
Actinobacteria abundance may have a role in 
neuropsychiatric disorders, while Bifidobacterium spp are 
considered to have a protective role by several studies, 
while in other studies, they seem to be key-driver [31-33]. 
Regarding the micronutrients, increased Copper and 
Copper/zinc ratio are associated with attention deficit. 
Dysbiosis and the destruction of the intestinal barrier 
function was found to be a risk factor for the occurrence 
and worsening of the chronic kidney disease. The 
mechanisms involved are chronic inflammation and 
increased productions of uremic toxins [34-37]. 
1.4 DNA damage 
The accumulation of DNA deteriorations destabilizes 
the human genome, promoting aberrant cells (pre - / 
cancerous) to preserve or to accelerate mutations. Gut 
microorganisms may be a serious source of DNA 
mutagens. For instance, studies have proven that some 
Enterococcus spp provide reactive oxygen species, such as 
hydroxyl free radicals, that cause DNA alterations, point 
mutations, protein-DNA crosslinking, destabilizing 
colorectal cancer-related genes. Enterotoxigenic 
Bacteroides fragilis triggers spermine oxidase expression 
on colonic epithelial cells, promoting DNA deteriorations. 
Furthermore, PKS-positive Escherichia Coli stimulates 
DNA double-strand breaks, cell cycle arrest and 
aneuploidy cell division. All these findings prove that 
microorganisms may induce DNA alterations and 
destabilize the genome directly or indirectly. Thus, the gut 
microbiome may be a risk factor and a treatment objective 
in colorectal cancer [38]. 
1.5 The modulation of cell proliferation 
To control the cell function and structure in normal 
tissues, there are signals that control the cell's growth and 
death. When perturbations of apoptotic signals and cell 
proliferation develop, they will promote continued cell 
proliferation, thus forming malignant tumors. 
Enterotoxigenic Bacteroides fragilis drop Bacteroides 
fragilis toxin (fragilysin) to promote E-cadherin cleavage, 
promoting beta-catenin nuclear translocation, 
transcriptional upregulation of the proto-oncogene c-Myc, 
and colonic cell proliferation. Identically, fusobacterium 
nucleatum connects to E-cadherin through FadA, 
triggering downstream pathways and promoting cell 
proliferation. In conclusion, studies have proven that 
dysbiosis is a cause of aberrant epithelial cell proliferation 
and early tumor development [37]. 
2. Gut microbiota and colorectal cancer – is there any 
link? 
Colorectal cancer is the fourth most frequent type of 
cancer worldwide, with a total of 8.5% of all new cases of 
cancer/ year, thus being a major health problem [39]. The 
development of this complex malignant disorder 
contributes to a large amount of factors, including 
environmental risk and genetic factors [40]. Considering 
that less than 20% of the cases are hereditary, we can 
conclude that environmental risk factors play a decisive 
role, including alcohol consumption, smoking, diabetes, 
obesity, a diet rich in animal fat, processed foods, red meat, 
low intake of fruits and fibers [31,40]. Studies show that 
genetic and epigenetic alterations in proto-oncogenes, 
tumor suppressor genes and DNA repair genes, contribute 
to the tumor transformation of the normal colonic 
epithelium. Recently, studies have focused on gut 
microbiota examination, and reported alterations in 
colorectal cancer samples, indicating that the microbiome 
may be a crucial factor in the induction and evolution of 
colorectal cancer [41-43]. 
The gut microbiota contributes to the epithelial barrier 
function and mucosal homeostasis, efficiently keeping 
bacteria into the lumen. These function perturbations 
promote an increased intestinal permeability, which is 
correlated with many gastrointestinal diseases, such as 
irritable bowel syndrome, celiac disease, inflammatory 
bowel disease, and colorectal development. The gut 
microbiota metabolic products may also influence the 
immune response, activating pro-inflammatory mediators, 
such as interleukin-6, cytokines, and tumor necrosis factor 
– α, leading to epithelial cell damage [44]. Furthermore, 
bacterial species can cause inflammatory responses or 
produce toxins, thus damaging the epithelial cells directly. 
Examples: species of Bacteroides fragilis and 
Enterococcus faecalis generate enterotoxins and reactive 
oxygen inducing oxidative DNA damage; Bacteroides 
fragilis induces cellular proliferation by activating β-
catenin nuclear signaling; Fusobacterium nucleatum 
adheres and invades epithelial cells by the FadA surface 
protein [45,46]. 
Studies have shown that plenty of these bacterial 
species are found in different amounts in healthy 
individuals compared to colorectal cancer samples. Thus, 
microbiota in colorectal patients contains especially pro-
inflammatory opportunistic microorganisms and 
pathogens associated with metabolic disorders, and a 
reduced amount of butyrate-producing bacteria, which has 
a significant role in intestinal homeostasis [47]. Moreover, 
some bacterial species have a high prevalence in colorectal 
patients than healthy populations: Escherichia coli, 
Bacteroides fragilis, Enterococcus faecalis, Streptococcus 
gallolyticus, Fusobacterium nucleatum. Instead, types of 
bacteria such as Roseburia, Clostridium, Faecalibacerium 
and Bifidobacterium are reduced [48]. Studies focused on 
discovering oncobacteria, but no single species have been 
universally detected in all colorectal patients. This 
indicates that various associations of microorganisms may 
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act synergistically, and the modifications in both damaging 
or protective bacterial populations may be responsible for 
the development and evolution of colorectal cancer [49]. 
3. Microbiome – a tool in the early diagnosis of colorectal 
cancer? 
The development of colorectal cancer from normal 
mucosa is a complex multi-step process, from pre-
neoplastic lesions to adenomatous polyps to carcinoma 
proliferation, which may take about ten years to occur. This 
is the main reason why colorectal cancer is a malignancy 
that may be screened. Many countries have initiated 
population screening and prevention programs, using fecal 
occult blood test and the fecal immunochemical test, 
followed by colonoscopy when the tests are positive. Thus, 
precancerous proliferation may be detected, with a highly 
successful treatment, preventing colorectal cancer and 
improving the overall survival [50,51]. 
Current studies have focused on additional criteria that 
may be considered in the algorithms used to lead patients 
to colonoscopy, including molecular biomarkers connected 
to the processes of carcinogenesis, such as circulating 
tumor cells and cell-free DNA microRNAs, and 
metabolites from plasma samples [52]. 
As discussed above, microbiome alterations are 
associated with colorectal cancer, so the option of using 
different microbiome stool signatures has emerged. Even 
though there is no major difference in the overall 
composition of microbiota in colorectal patients and 
healthy individuals, the distinction involves plenty of key 
microorganisms. This is one of the reasons why colorectal 
cancer diagnosis needs to develop some specific tests for 
those suggestive species, without evaluating the whole 
microbiome. For example, Fusobacterium nucleatum has 
been persistently discovered in large amounts in the feces 
of patients with adenoma and colorectal cancer, compared 
to healthy humans and cancer tissue compared to 
circumferential normal tissue [53]. 
Even though efforts have been conducted to discover 
the bacterial biomarkers that may predict the risk of 
colorectal cancer, major factors such as genetics, lifestyle, 
and environmental factors are known to influence the 
composition of gut microbiota. Also, the quality of 
samples, experimental protocols, and bioinformatics tools 
are all influencing factors and may explain the differences 
between studies [54]. Regardless of the advances in 
bacterial signatures in colorectal cancer patients, the 
clinical routine is still not using microbiome biomarkers in 
the screening of colorectal cancer. 
In conclusion, the purpose of all this research is finding 
a superior prediction on colorectal cancer development, 
evolution and treatment strategies, by incorporating 
information on genetics with the microbiome, lifestyle, 
environmental factors to create new risk models. 
4. Dysbiosis – a treatment target of colorectal cancer 
The possibility of modulating the gut microbiome is a 
new therapeutic strategy in preventing and treating some 
disorders that are in direct relationship with the microbiota 
alterations. Considering the possible connection between 
colorectal cancer and microbiota previously mentioned, 
there is an increasing interest in discovering microbiome-
related treatments. However, therapy strategies include the 
use of pre- and probiotics, fecal microbiota transplantation 
and phage therapy [55]. 
Fecal microbiota transplantation has been used as a 
therapeutic method in inflammatory bowel diseases, 
irritable bowel disease, metabolic syndrome, obesity, 
atopy, multiple sclerosis, and favorable outcomes. There 
are no conclusive data from clinical trials in treating 
colorectal cancer by using fecal microbiota transplant 
[56]. 
Another direct strategy is using antibiotics to modulate 
the microbiome and indirectly influence colorectal cancer 
evolution, thus targeting some bacteria (Fusobacterium 
nucleatum, Bacteroides fragilis, Escherichia coli). One 
study showed that the therapy reduced the amount of 
Fusobacterium nucleatum and the tumor’s overall growth. 
Still, antibiotics may lead to dysbiosis and drug resistance. 
Therefore, there is a need for new products targeting 
bacteria more specifically. For example, a glycopolymer, 
antagonist of the Escherichia Coli virulence factor FimH, 
exposed a reduction in bacteria's adherence to the gut 
epithelia [57]. Furthermore, a low dose of a recombinant 
BFT-2 enterotoxin, which is a virulence factor of 
Bacteroides fragilis, reduced the tumor’s development in 
the colorectal cancer mouse model [58]. Another major 
factor is the interaction between the microbiome and the 
viral component, and its modulation by phage therapy, due 
to its role in combating antibiotic-resistant microorganisms 
[59]. 
Another promising treatment strategy, affecting the 
immune response and metabolic pathways, is diet-keeping 
and vitamin D administration as an anti-neoplastic effect. 
[60] It is one of the most significant factors shaping the 
human microbiome, as studies have shown that alterations 
induced by deoxycholic acid developed carcinogenesis. At 
the same time, high dietary fiber and butyrate-producing 
bacteria may considerably reduce tumor growth [61]. 
Studies showed that the microbiome might affect the 
response of 2 cancer immunotherapeutic agents (anti-
CTLA4 and anti-PD-L1), by amplifying the activation of 
dendritic and anti-tumor T cells responses [62-64]. Also, 
the immunologic stimulation by Bacteroides spp and 
Bifidobacterium spp affects the efficacy of the therapy. 
Furthermore, it has been proven that the imbalance of 
dietary sphingolipids may influence the effectiveness of 
chemotherapy and radiotherapy [64]. 
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Probiotics regulate pathogenic microorganisms and the 
immune response, which may reduce blood cholesterol, 
colitis and prevent colorectal cancer, using different 
mechanisms: releasing detoxifying agents, anti-
inflammatory factors, anti-carcinogenesis compounds 
(anti-angiogenesis), short-chain fatty acids that increase 
the intestinal barrier function [65]. For example, butyrate-
producing species such as Clostridium butyricum and 
Bacillus subtilis may have an anti-tumor effect; 
Lactobacillus casei (strain BL23) may suppress colorectal 
cancer by targeting intestinal dysbiosis [66], while 
Lactobacillus casei (strain ATCC 334) produce 
ferrochrome which prevents colorectal cancer evolution by 
apoptosis mediated through the c-Jun N-terminal kinase 
pathway [67], and Lactobacillus casei (rhamnosus Lcr35) 
inhibit intestinal mucositis [68,69]. 
As already mentioned above, the intestinal 
microbiome, through the stimulation of the immune 
system, has a natural anti-carcinogenesis effect, so, it has 
been suggested as a key mechanism of cancer 
immunotherapy. There are three known ways: microbial 
antigens activate T-cell response with activating tumor-
specific immune response (Bifidobacteria spp, 
Akkermansia muciniphilia, Bacteroides spp, Enterococcus 
hirae), the activation of pattern recognition receptors that 
mediate pro-immune and anti-inflammatory effects and the 
release of small metabolites that mediate systemic effects 
in the host (polyamines, vitamin, desaminotyrosine) [70]. 
All these data show the importance of new treatment 
strategies in different types of cancer, including colorectal 
cancer, meaning combined chemo- and immunotherapy 
with adjuvant therapies aiming the intestinal microbiota, 
such as diet, pre- and probiotics and vitamin D 
supplementation [71]. 
Conclusions 
Despite the implemented screening programs many 
countries have already adopted, colorectal cancer remains 
a serious public health issue, being the third leading cause 
of cancer death. For this reason, research must continue to 
explore new strategies regarding the prevention, 
prediction, diagnosis and treatment options. Considering 
the major roles gut microbiota has on metabolism, nutrition 
and the immune system, as well as, tumorigenesis induced 
by DNA alterations due to dysbiosis, further research is 
expected to discover specific microorganisms and their 
metabolites connected to colorectal cancer induction and 
progression. This may provide new tools in the clinical 
management of colorectal cancer patients.  
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